Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Sheng-Min | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Lee, Soo-Jung | - |
dc.contributor.author | Jun, Tae-Youn | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.contributor.author | Pae, Chi-Un | - |
dc.date.accessioned | 2021-09-03T11:37:52Z | - |
dc.date.available | 2021-09-03T11:37:52Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01 | - |
dc.identifier.issn | 0022-3956 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/85096 | - |
dc.description.abstract | Attention-deficit/hyperactivity disorder (ADHD) is one of the most common and a debilitating neurobehavior disorder in the pediatric population. Although numerous effective psychostimulants are available, more than 30% of patients still do not show adequate treatment response rendering diverse pharmacological options. We aimed at assessing the efficacy and safety of modafinil in the treatment of children and adolescents with ADHD by conducting a meta-analysis. An extensive search of databases and clinical trial registries resulted in five published short-term randomized, double-blind, placebo controlled trials. Primary efficacy measures were mean change in ADHD Rating Scale-IV Home (ADHDRS-IV Home) and School Version (ADHD-RS-IV School) from baseline to study end point. The results showed that modafinil more significantly improved ADHD-RS-IV Home (SMD, -0.77 [95%CI, -1.11 to -0.441) and School (SMD, -0.71 [95%Cl, -0.96 to -0.47]) than placebo. Dropout rate due to adverse event did not significantly differ between two groups. In terms of commonly observed side effects, modafinil showed significantly higher incidence of decreased appetite (RR = 5.02, 95% CIs, 2.55 to 9.89, P < 0.00001) and insomnia (RR = 6.16, 95% CIs, 3.40 to 11.17, P < 0.00001). Modafinil did not cause a clinically significant increase of heart rate, systolic blood pressure, and diastolic blood pressure. Although we found that modafinil may be another treatment option in children and adolescents with ADHD, the results should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of clinical trials. (C) 2016 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | FILM-COATED TABLETS | - |
dc.subject | OBSTRUCTIVE SLEEP-APNEA | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | INDUSTRY SPONSORSHIP | - |
dc.subject | CHILDREN | - |
dc.subject | ADOLESCENTS | - |
dc.subject | DEFICIT | - |
dc.subject | METHYLPHENIDATE | - |
dc.subject | VORTIOXETINE | - |
dc.subject | ARMODAFINIL | - |
dc.title | Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1016/j.jpsychires.2016.09.034 | - |
dc.identifier.scopusid | 2-s2.0-84994259819 | - |
dc.identifier.wosid | 000390733100036 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PSYCHIATRIC RESEARCH, v.84, pp.292 - 300 | - |
dc.relation.isPartOf | JOURNAL OF PSYCHIATRIC RESEARCH | - |
dc.citation.title | JOURNAL OF PSYCHIATRIC RESEARCH | - |
dc.citation.volume | 84 | - |
dc.citation.startPage | 292 | - |
dc.citation.endPage | 300 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | FILM-COATED TABLETS | - |
dc.subject.keywordPlus | OBSTRUCTIVE SLEEP-APNEA | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | INDUSTRY SPONSORSHIP | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | ADOLESCENTS | - |
dc.subject.keywordPlus | DEFICIT | - |
dc.subject.keywordPlus | METHYLPHENIDATE | - |
dc.subject.keywordPlus | VORTIOXETINE | - |
dc.subject.keywordPlus | ARMODAFINIL | - |
dc.subject.keywordAuthor | Modafinil | - |
dc.subject.keywordAuthor | ADHD | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | Treatment | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.